Exclusive: Activist Ananym plans to launch proxy fight at Henry Schein, sources say
Activist investor Ananym Capital Management plans to nominate as many as half a dozen directors to the board at Henry Schein ...
Henry Schein price target raised to $80 from $77 at Jefferies
Jefferies raised the firm’s price target on Henry Schein (HSIC) to $80 from $77 and keeps a Hold rating on the shares. Management has a strong ...
Jefferies Issues a Hold Rating on Henry Schein (HSIC)
Jefferies analyst Glen Santangelo assigned a Hold rating to Henry Schein (HSIC – Research Report) today and set a price target of $80.00. The ...
Activist investor Ananym plans to start proxy fight at Henry Schein - Reuters
Activist investor Ananym Capital Management to nominate directors to Henry Schein board, pushing for CEO change and cost ...
Zacks.com on MSN7d
HSIC Stock Might Rise Following the Acquisition of Acentus
Henry Schein, Inc. HSIC recently completed the acquisition of substantially all of the assets of Acentus, a national medical ...
Ananym Capital to nominate directors for Henry Schein board - Reuters
Ananym Capital Management, an activist investor, has plans to nominate up to six directors to the board of Henry Schein ...
bovnews5d
Henry Schein, Inc. (HSIC) Stock Settles at $73.22: What’s Contributing to This Price Point?
Henry Schein, Inc. (HSIC) stock saw a modest uptick, ending the day at $73.22 which represents a slight increase of $1.47 or 2.05% from the prior close of $71.75. The stock opened at $72.23 and ...
Henry Schein, Inc. (NASDAQ:HSIC) Given Average Rating of “Moderate Buy” by Brokerages
Shares of Henry Schein, Inc. (NASDAQ:HSIC – Get Free Report) have been assigned an average recommendation of “Moderate Buy” ...
Nasdaq7d
HSIC Stock Might Rise Following the Acquisition of Acentus
Henry Schein, Inc. HSIC recently completed the acquisition of substantially all of the assets of Acentus, a national medical supplier specializing in the delivery of continuous glucose monitors ...